Search for any words: Search

  Heller, Glenn                    

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19)   

Aggarwal, Rahul ,  Eggener, Scott ,  Chen, Ronald ,  Heller, Glenn ... -  ASCO   -  J Clin Oncol   -  2018    

Abstract -  No-Endpoint -  Trial-Description-Only -  GU -  AFT-19

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer      

Eastham, James A. ,  Heller, Glenn ,  Halabi, Susan ... -    -  J. Clin. Oncol   -  2020    

Manuscript -  Primary -  Primary -  GU -  CALGB-90203

Baseline testosterone levels in men with clinically localized high-risk prostate cancer treated with radical prostatectomy with or without neoadjuvant chemohormonal therapy (Alliance)      

Eastham, James A. ,  Heller, Glenn ,  Hillman, David W. ... -    -  J Urol   -  2021    

Manuscript -  Secondary-not-in-original -  Primary -  GU -  CALGB-90203

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)   

Morris, Michael J. ,  Heller, Glenn ,  Bryce, Alan ,  Armstrong, Andrew ... -  ASCO   -  J Clin Oncol   -  2019    

Abstract -  Primary -  Primary -  GU -  A031201

CASPAR (Alliance A031902) - A Randomized, Phase III Trial of Enzalutamide with/without Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)   

Rao, Arpit ,  Ryan, Charles J ,  Vanderweele, David ,  Heller, Glenn ... -  ASCO GU   -  J Clin Oncol   -  2021    

Abstract -  No-Endpoint -  Trial-Description-Only -  GU -  A031902